New Analysis Shows Repatha ® (Evolocumab) Reduces Cardiovascular Events In Patients With History Of Stroke

THOUSAND OAKS, Calif., Aug. 29, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a new analysis showed lowering low-density lipoprotein cholesterol (LDL-C) levels with Repatha® (evolocumab) reduced the risk of cardiovascular events in a sub-group of patients with a history of stroke from the Repatha cardiovascular outcomes study (FOURIER). No new safety concerns were identified in this cohort of more than 5,000 patients. Detailed results were presented today in a Late-Breaking Clinical Trials session at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, Spain. "The clinical benefits of PCSK9 inhibition in stroke patients have not been previously reported. T...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news